CEL-SCI Stock
CEL-SCI Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Geert R. Kersten
- Employees
- 43
- Market cap
- $31 M
- IPO
- 08/12/1983
- Web
- cel-sci.com
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds…
CEL-SCI stock: price history
1D
+2.9%
1W
-7.7%
1M
+20.9%
6M
-63.8%
YTD
-66.0%
1Y
-81.4%
2Y
-95.0%
5Y
-99.5%
10Y
-99.1%
Next earnings date
Next earnings date
23/12/2026 (in 67 days)
Volatility around earnings
~3% weaker price swings than usual
Ask the agents about CEL-SCI
Analyst assessment of CEL-SCI
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 12/07/2023
CEL-SCI stock metrics
P/E
-0.69
P/B
1.98
EV/EBITDA
-1.78
RETURN ON EQUITY
-51.7%
NET MARGIN
0.0%
DEBT/EQUITY
0.72
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.1%
FLOAT SHARES
16,367,602
AVG. DAILY VOLUME (30D)
235,517
Insider transactions (SEC)
KERSTEN GEERT R
PRICHEP PATRICIA B
TALOR EYAL
KERSTEN GEERT R
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about CEL-SCI stock
What does CEL-SCI do?
CEL-SCI Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Geert R. Kersten, the company employs around 43 people.
The IPO was on 08/12/1983; the stock trades on AMEX under the ticker CVM.
What do analysts say about CEL-SCI stock?
6 analysts rate the stock, the consensus is Buy (as of 12/07/2023).
This is an external assessment, not a statement by Market Jury.
When does CEL-SCI report next?
The next earnings date is 23/12/2026.
Around past earnings, price swings were roughly -3% stronger than usual.
Does CEL-SCI pay a dividend?
Yes. The last dividend was US$0.01 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to CEL-SCI?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get CEL-SCI stock analyzed?
Clicking "Analyze stock" lets five strategies assess CEL-SCI against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.